There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celldex (CLDX – Research Report) and Biophytis (BPTS – Research Report) with bullish sentiments.
Celldex (CLDX)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex, with a price target of $65.00. The company’s shares closed last Friday at $40.12.
According to TipRanks.com, Slutsky is a 4-star analyst with an average return of
Celldex has an analyst consensus of Strong Buy, with a price target consensus of $64.60, a 58.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $73.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Biophytis (BPTS)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Biophytis today and set a price target of $15.00. The company’s shares closed last Friday at $0.42, close to its 52-week low of $0.35.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Biophytis has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLDX:
- Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
- Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
- Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
